

Date: 20 December 2024

To

| | |
|---|--|
| The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 544293 | The Secretary National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 Scrip Symbol : SURAKSHA |
|---|--|

Dear Sir / Ma'am,

Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Sub: Press release in respect of unaudited financial results (both standalone and consolidated) of the Company for quarter and six months ended 30 September 2024

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the unaudited financial results (both standalone and consolidated) of the Company for quarter and six months ended 30 September 2024.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated July 14, 2023, and NSE's Circular No. NSE/CML/2023/57 dated July 14, 2023, are as under:

Date of occurrence of Event/Information: 20 December 2024

Time of occurrence of Event/Information: 06.55 pm

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

Mamta Jain

Company Secretary and Compliance Officer

Membership No.: ACS 25654

Encl: As above

Suraksha Diagnostic Limited

(Formerly known as Suraksha Diagnostic Private Limited)

CIN: U85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town
Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750


Suraksha Diagnostic Limited Reports Robust Q2 & H1 FY25 Performance

H1 FY25 Total Income grows 14.5% YoY

EBITDA jumps 24.9% with margins improving by 300+ basis points Y-o-Y to reach 36.3%

Kolkata, 20th December 2024: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and half year ended September 30, 2024.

H1 FY25 Financial Performance Snapshot (Y-o-Y)



Key Financial Highlights

| Particulars (INR Mn) | Q2 FY25 | Q2 FY24 | Y-o-Y | Q1 FY25 | Q-o-Q | H1 FY25 | H1 FY24 | Y-o-Y |
|----------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Total Income | 680.7 | 606.0 | 12.3% | 618.5 | 10.1% | 1,299.2 | 1,134.2 | 14.5% |
| EBTIDA | 245.1 | 213.9 | 14.6% | 217.2 | 12.8% | 462.3 | 370.1 | 24.9% |
| EBTIDA Margin (%) | 36.7% | 35.6% | | 35.8% | | 36.3% | 33.1% | |
| PAT | 101.6 | 83.4 | 21.8% | 76.7 | 32.5% | 178.2 | 122.7 | 45.3% |
| PAT Margin (%) | 15.2% | 13.9% | | 12.6% | | 14.0% | 11.0% | |

Highlights:

- Revenue from operations for the quarter stood at INR 667.5 Mn with a growth of 11.2% Y-o-Y. For H1 FY25, the corresponding figure was INR 1,274.9 Mn with a growth of 14.1%
- EBITDA for Q2 FY25 stood at INR 245.1 Mn as compared to INR 213.9 Mn in Q2 FY24 representing a growth of 14.6% y-o-y
- The company recorded an EBITDA margin of 36.7% in Q2 FY25 compared to 35.6% for the same quarter last year. EBITDA for H1 FY25 stood at INR 462.3 Mn, up by 24.9%, while the margins stood at 36.3%
- PAT for Q2 FY25 stood at INR 101.6 Mn as compared to INR 83.4 Mn in Q2 FY24, representing a growth of 21.8% Y-o-Y. PAT margin for the quarter stood at 15.2%, up by more than 130 basis points from the same quarter last year. PAT for H1 FY25 stood at INR 178.2 Mn, up by 45.3%
- As of September 2024, the company's consolidated net cash stood at INR 498.39 Mn compared to INR 463.86 Mn at the end of FY24

Commenting on the Results Ms Ritu Mittal, Joint Managing Director & CEO said, -

We are pleased to report strong financial performance for the second quarter and first half of FY25. Our focus on operational efficiency, revenue growth, has translated into robust results, reflecting our ability to navigate the business landscape effectively.

Over the years, we have been able to drive consistent improvement in revenue per patient and EBITDA per patient which stood at INR 2,099 and INR 761, respectively in H1 FY25. We believe we are on a solid footing to win, given the changing customer preference towards organized diagnostic chains from standalone centres.

West Bengal continues to be the prominent market for our company, with 47 out of the total 51 centers located in the state. We remain committed in our endeavor to drive further growth from the Eastern and North-Eastern markets in India. We believe the strong results position us well to drive sustainable top-line and margin growth.

As a publicly listed entity, we remain committed to enhancing shareholder value by executing on our well-defined strategies to expand into our core markets and also exploring inorganic growth opportunities. In conclusion, I would like to thank all stakeholders, past and present, and hope for continued support as we strive to reach scale newer summits.

About Suraksha Diagnostic Limited:

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar, Assam and Meghalaya.

The company's central reference laboratory is accredited by the College of American Pathologists, while the 3 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centers are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

| Company: Suraksha Diagnostic Limited | Investor Relations: Orient Capital |
|--|--|
| Email: investors@surakshanet.com | Name: Mr. Ashish Tendulkar Email: ashish.tendulkar@linkintime.co.in Tel: +91 9820953312 |
| CIN: U85110WB2005PLC102265 | Name: Pooja Swami Email: pooja.swami@linkintime.co.in Tel: +91 9860202359 |
| Website: https://www.surakshanet.com/ | |

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.